New HIV injection tested in early safety trial
NCT ID NCT06560489
Summary
This early-stage study tested the safety of a new injectable drug called LP-98 in people recently diagnosed with HIV who had not yet started standard treatment. Forty participants received different doses of the drug via injection every two weeks for about two months. The main goal was to check for side effects and see how the body handles the medication, while also measuring its initial impact on the HIV virus and immune cells.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HIV are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Henan Provincial Hospital for Infectious Diseases (Zhengzhou Sixth People's Hospital)
Zhengzhou, Henan, China
Conditions
Explore the condition pages connected to this study.